Over one billion people worldwide are affected by gastrointestinal illness, and in the US alone this results in $21 billion of direct and indirect costs each year.
Despite the range of underlying mechanisms that can cause gastrointestinal disease, the symptoms experienced largely overlap, making diagnosis challenging. There is a significant unmet need in the clinic for better, non-invasive tests to better distinguish between GI diseases and tests that allow for monitoring overtime to establish treatment success, particularly for complex conditions such as IBS. Exhaled breath contains a vast array of chemicals that can originate from the gastrointestinal tract: from underlying metabolism, inflammation, and the microbiome.
Through our patient-centric brand OMED Health, we currently provide hydrogen and methane breath tests that aid clinicians in the diagnosis and treatment of SIBO, lactose intolerance, and fructose intolerance breath tests. These microbiome test kits are suitable for at-home collection of breath, so can support de-centralized clinical trial designs including the collection of breath composition data throughout time.
Introducing, the Microbiome Panel
Absolute quantification of 18 microbial metabolites with high accuracy,
confirmed against reference spectra.
If you are interested in incorporating breath biomarkers into your research, the Microbiome Panel is the perfect way to begin. For those interested in learning more, we have some useful content discussing VOC biomarkers, the fundamentals of breath analysis and why microbiome-derived compounds appear in breath and how we measure them. The gut microbiome, alongside the linear connection to gastrointestinal research, can also influence many other disease states, so can also be useful for those conducting respiratory, infection or metabolic studies.
The Panel includes:
- Lease of the Breath Biopsy Collection Station for the duration of your study – enabling reproducible breath sample collection at the clinical site to maximize signal to noise ratio.
- TD-GC-MS analysis using high-resolution accurate mass (HRAM) Q Exactive Orbitrap systems within our laboratories.
- A quantitative data report on the Panel of 18 volatile microbial metabolites that are routinely seen in exhaled breath with reference datasets available in the Breath Biopsy VOC Atlas®. These are presented in table format including compound IDs. These data are supplemented with statistical analysis to investigate specific study objectives, delivered by Owlstone’s expert in-house breathomics team.
- Priced per sample, get in touch for further information.
FURTHER READING
Other recommended reading:
- ARTICLE: ‘Gut Microbiome Biomarkers for Disease Diagnosis’ – The Microbiologist
- DOCUMENT: ‘Quick Start Guide: Incorporate Breath Analysis into Microbiome Research
- POSTER: Changes in exhaled volatile organic compounds following iron supplementation in self-reported healthy adults
- CASE STUDY: Breath metabolites provide fresh insight into the gut microbiome
- POSTER: The feasability of measuring VOCs on breath in response to a lactulose challenge